• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
PNV
Click for more information
0.50% $1.98

POLYNOVO LIMITED - Announcements

Market Cap $1.699B  ! watchlist Created with Sketch. Add to my watchlist

PolyNovo Limited is an Australia-based medical device company, which is focused on... PolyNovo Limited is an Australia-based medical device company, which is focused on advanced wound care that designs, develops, and manufactures dermal regeneration solutions using its patented NovoSorb biodegradable polymer technology. Its solutions include NovoSorb Biodegradable Temporizing Matrix (BTM) and NovoSorb MTX. NovoSorb BTM is a synthetic, biodegradable and biocompatible device designed to facilitate the dermis to grow within a patented polyurethane matrix when lost through extensive surgery, trauma or burn. NovoSorb BTM is indicated for use in the management of wounds, including partial and full thickness wounds, pressure ulcers, venous and diabetic ulcers, chronic and vascular ulcers, surgical wounds, trauma wounds and draining wounds. Its development program covers breast sling, hernia, and orthopedic applications. NovoSorb MTX is available in a range of sizes to address acute and chronic dermal wounds and is comprised of a 2mm biodegradable foam with no sealing membrane.More

Corporate Spotlight
Not Yet Available

Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.

Claim your IR profile arrow Created with Sketch.
See benefits

Announcements


Plus500
Plus500
ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
TRADE NOW
TRADE NOW
Plus500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
TRADE NOW

Filter Results
All Price Sensitive Only
search Created with Sketch. Search
search Created with Sketch. Search
Filters [Clear]
  • Price Sensitive: Yes
PNV S&P DJI Announces September 2019 Quarterly RebalancePRICE SENSITIVE06/09/19 download Created with Sketch. 148.88KB
PNV Half Yearly Report and AccountsPRICE SENSITIVE21/02/19
PNV PolyNovo Purchases additional production facilityPRICE SENSITIVE18/01/19
PNV Malaysia Regulatory ApprovalPRICE SENSITIVE18/01/19
PNV H1 Sales FY19 PolyNovoPRICE SENSITIVE07/01/19
PNV PolyNovo Sales FY19 YTD Market UpdatePRICE SENSITIVE28/11/18
PNV AGM Chairman and CEO Address to ShareholdersPRICE SENSITIVE16/11/18
PNV NovoSorb BTM aaproved for sale in IndiaPRICE SENSITIVE01/11/18
PNV S&P DJI Announces September 2018 Quarterly RebalancePRICE SENSITIVE07/09/18
PNV Annual Report to Shareholders and Appendix 4EPRICE SENSITIVE16/08/18
PNV Final Patient enrolled in BARDA Feasibility Burn TrialPRICE SENSITIVE02/08/18
PNV NovoSorb BTM approved for sale in Saudi ArabiaPRICE SENSITIVE27/07/18 download Created with Sketch. 154.34KB
PNV Final patient enrolled in CE Mark Burn TrialPRICE SENSITIVE22/05/18 download Created with Sketch. 134.93KB
PNV PolyNovo Announces Breast Device Development ProgramPRICE SENSITIVE03/04/18
PNV Results announcement, App 4D and Half-Year Financial ReportPRICE SENSITIVE15/02/18
PNV PolyNovo Announces Breast Device Development AgreementPRICE SENSITIVE18/01/18
PNV PolyNovo signs MOU for global breast partnershipPRICE SENSITIVE16/10/17
PNV New Sales and Repeat Orders in the USPRICE SENSITIVE11/10/17
PNV PolyNovo's Israel Market EntryPRICE SENSITIVE04/10/17
PNV Share Purchase Plan (SPP) OfferPRICE SENSITIVE02/10/17
PNV Placement and Share Purchase PlanPRICE SENSITIVE25/09/17
PNV Trading HaltPRICE SENSITIVE21/09/17
PNV Further US Sales for NovoSorb BTMPRICE SENSITIVE14/09/17
PNV First US Sales of BTM NovosorbPRICE SENSITIVE01/09/17
PNV Annual Report to shareholders and Appendix 4EPRICE SENSITIVE24/08/17
PNV Business update and earnings guidancePRICE SENSITIVE19/05/17
PNV Research project collaboration with Beta Cell TechnologiesPRICE SENSITIVE12/05/17
PNV Additional Success US BTM usePRICE SENSITIVE27/02/17
PNV First BTM patient in USPRICE SENSITIVE23/02/17
PNV Results announcement, App 4D and Half-Year Financial ReportPRICE SENSITIVE21/02/17
PNV South Africa first order for BTMPRICE SENSITIVE17/02/17
PNV First stock purchasePRICE SENSITIVE22/12/16
PNV PolyNovo's South Africa Market EntryPRICE SENSITIVE08/12/16
PNV US Market Entry-PolyNovo-PNV.AX PRICE SENSITIVE03/10/16
PNV Full Year Statutory Accounts and Appendix 4E-PNV.AX PRICE SENSITIVE22/08/16
PNV Financial result guidance-PNV.AX PRICE SENSITIVE08/08/16
PNV Additional BARDA Option Exercised Valued at US$2.4m-PNV.AX PRICE SENSITIVE31/05/16
PNV Trading Halt-PNV.AX PRICE SENSITIVE30/05/16
PNV Half Yearly Report and AccountsPRICE SENSITIVE19/02/16
PNV Financial Result GuidancePRICE SENSITIVE12/02/16
PNV US FDA approvalPRICE SENSITIVE04/01/16
PNV PolyNovo's US FDA approvalPRICE SENSITIVE29/12/15
PNV PolyNovo completes acquisition of minoritiesPRICE SENSITIVE22/12/15
PNV PolyNovo acquires minority interestsPRICE SENSITIVE25/11/15
PNV Placement and Share Purchase PlanPRICE SENSITIVE25/11/15
PNV Trading HaltPRICE SENSITIVE23/11/15
PNV Final Patient Recruited in Adelaide Burn TrialPRICE SENSITIVE20/10/15
PNV PolyNovo Awarded BARDA Contract for Burns TrialPRICE SENSITIVE29/09/15
PNV Trading HaltPRICE SENSITIVE28/09/15
PNV App 4E / Full Year Statutory AccountsPRICE SENSITIVE20/08/15
PNV Financial Result GuidancePRICE SENSITIVE14/08/15
PNV Clinical Paper on Patient follow up of PolyNovo BTMPRICE SENSITIVE01/07/15
PNV PolyNovo Burn Trial Receives Ethics Approval at The AlfredPRICE SENSITIVE15/06/15
PNV CE Mark Clinical Trial for BTM in Severe BurnsPRICE SENSITIVE08/05/15
PNV PolyNovo Divests AOD9604PRICE SENSITIVE30/04/15
PNV Half Yearly Report and AccountsPRICE SENSITIVE23/02/15
PNV Half Year Financial Result GuidancePRICE SENSITIVE17/02/15
PNV New Chief Executive Officer and Head of Regulatory AffairsPRICE SENSITIVE13/02/15
PNV S&P DJI Announces September 2019 Quarterly Rebalance
06/09/19PRICE SENSITIVE download Created with Sketch. 148.88KB
PNV Half Yearly Report and Accounts
21/02/19PRICE SENSITIVE
PNV PolyNovo Purchases additional production facility
18/01/19PRICE SENSITIVE
PNV Malaysia Regulatory Approval
18/01/19PRICE SENSITIVE
PNV H1 Sales FY19 PolyNovo
07/01/19PRICE SENSITIVE
PNV PolyNovo Sales FY19 YTD Market Update
28/11/18PRICE SENSITIVE
PNV AGM Chairman and CEO Address to Shareholders
16/11/18PRICE SENSITIVE
PNV NovoSorb BTM aaproved for sale in India
01/11/18PRICE SENSITIVE
PNV S&P DJI Announces September 2018 Quarterly Rebalance
07/09/18PRICE SENSITIVE
PNV Annual Report to Shareholders and Appendix 4E
16/08/18PRICE SENSITIVE
PNV Final Patient enrolled in BARDA Feasibility Burn Trial
02/08/18PRICE SENSITIVE
PNV NovoSorb BTM approved for sale in Saudi Arabia
27/07/18PRICE SENSITIVE download Created with Sketch. 154.34KB
PNV Final patient enrolled in CE Mark Burn Trial
22/05/18PRICE SENSITIVE download Created with Sketch. 134.93KB
PNV PolyNovo Announces Breast Device Development Program
03/04/18PRICE SENSITIVE
PNV Results announcement, App 4D and Half-Year Financial Report
15/02/18PRICE SENSITIVE
PNV PolyNovo Announces Breast Device Development Agreement
18/01/18PRICE SENSITIVE
PNV PolyNovo signs MOU for global breast partnership
16/10/17PRICE SENSITIVE
PNV New Sales and Repeat Orders in the US
11/10/17PRICE SENSITIVE
PNV PolyNovo's Israel Market Entry
04/10/17PRICE SENSITIVE
PNV Share Purchase Plan (SPP) Offer
02/10/17PRICE SENSITIVE
PNV Placement and Share Purchase Plan
25/09/17PRICE SENSITIVE
PNV Trading Halt
21/09/17PRICE SENSITIVE
PNV Further US Sales for NovoSorb BTM
14/09/17PRICE SENSITIVE
PNV First US Sales of BTM Novosorb
01/09/17PRICE SENSITIVE
PNV Annual Report to shareholders and Appendix 4E
24/08/17PRICE SENSITIVE
PNV Business update and earnings guidance
19/05/17PRICE SENSITIVE
PNV Research project collaboration with Beta Cell Technologies
12/05/17PRICE SENSITIVE
PNV Additional Success US BTM use
27/02/17PRICE SENSITIVE
PNV First BTM patient in US
23/02/17PRICE SENSITIVE
PNV Results announcement, App 4D and Half-Year Financial Report
21/02/17PRICE SENSITIVE
PNV South Africa first order for BTM
17/02/17PRICE SENSITIVE
PNV First stock purchase
22/12/16PRICE SENSITIVE
PNV PolyNovo's South Africa Market Entry
08/12/16PRICE SENSITIVE
PNV US Market Entry-PolyNovo-PNV.AX
03/10/16PRICE SENSITIVE
PNV Full Year Statutory Accounts and Appendix 4E-PNV.AX
22/08/16PRICE SENSITIVE
PNV Financial result guidance-PNV.AX
08/08/16PRICE SENSITIVE
PNV Additional BARDA Option Exercised Valued at US$2.4m-PNV.AX
31/05/16PRICE SENSITIVE
PNV Trading Halt-PNV.AX
30/05/16PRICE SENSITIVE
PNV Half Yearly Report and Accounts
19/02/16PRICE SENSITIVE
PNV Financial Result Guidance
12/02/16PRICE SENSITIVE
PNV US FDA approval
04/01/16PRICE SENSITIVE
PNV PolyNovo's US FDA approval
29/12/15PRICE SENSITIVE
PNV PolyNovo completes acquisition of minorities
22/12/15PRICE SENSITIVE
PNV PolyNovo acquires minority interests
25/11/15PRICE SENSITIVE
PNV Placement and Share Purchase Plan
25/11/15PRICE SENSITIVE
PNV Trading Halt
23/11/15PRICE SENSITIVE
PNV Final Patient Recruited in Adelaide Burn Trial
20/10/15PRICE SENSITIVE
PNV PolyNovo Awarded BARDA Contract for Burns Trial
29/09/15PRICE SENSITIVE
PNV Trading Halt
28/09/15PRICE SENSITIVE
PNV App 4E / Full Year Statutory Accounts
20/08/15PRICE SENSITIVE
PNV Financial Result Guidance
14/08/15PRICE SENSITIVE
PNV Clinical Paper on Patient follow up of PolyNovo BTM
01/07/15PRICE SENSITIVE
PNV PolyNovo Burn Trial Receives Ethics Approval at The Alfred
15/06/15PRICE SENSITIVE
PNV CE Mark Clinical Trial for BTM in Severe Burns
08/05/15PRICE SENSITIVE
PNV PolyNovo Divests AOD9604
30/04/15PRICE SENSITIVE
PNV Half Yearly Report and Accounts
23/02/15PRICE SENSITIVE
PNV Half Year Financial Result Guidance
17/02/15PRICE SENSITIVE
PNV New Chief Executive Officer and Head of Regulatory Affairs
13/02/15PRICE SENSITIVE
refresh Created with Sketch. REFRESH
 
(20min delay)
Last
$1.98 		Change
-0.010(0.50%) 		Mkt cap ! $1.699B
Open High Low Value Volume
$2.05 $2.05 $1.97 $1.316M 660.1K

Buyers (Bids)

No. Vol. Price($)
4 6709 $1.97
 

Sellers (Offers)

Price($) Vol. No.
$1.98 7699 4
View Market Depth
Last trade - 16.10pm 22/11/2024 (20 minute delay) ?
Last
$1.98 		  Change
-0.010 ( 0.12 %)
Open High Low Volume
$2.04 $2.05 $1.97 273126
Last updated 15.59pm 22/11/2024 ?
PNV (ASX) Chart

Top Stories

Bigtincan's Board backs Investcorp offer: Why a NASDAQ listing could be game-changing

Bigtincan Holdings has fielded an offer from Investcorp. But if you think it's underwhelming – consider Wall Street volumes.
Scientific conference spotlights PYC's work on blindness disease treatment PYC Therapeutics Ltd will have data from its ongoing trial into a drug candidate to treat Retinitis Pigmentosa type 11 presented in Singapore
Pan Asia rebranding to 'clear confusion' after bagging $35M for Chile projects Pan Asia Metals has scored $35 million from a New York private equity firm at the same time as the company's big rebrand push begins.
Sales growth pushes Lovisa's fortunes (and shares) upwards Lovisa Holdings Ltd has seen its shares rise more than 2% following a sales update, and on a good day for the consumer discretionary sector
Week 47 Wrap: HotCopper users' most watched; Brent lifts on Putin's scary letter; RFK dents CSL Welcome to the end of another week. Let's start with what HotCopper users have been watching and discussing.
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.